Articles

AI is put to work on NASH biomarkers

iBiopsy study shows promise in diagnosing severity of disease in patients
Written byLori Lesko
| 3 min read

SOPHIA ANTIPOLIS, France—Median Technologies, The Imaging Phenomics Company, recently announced the results of an artificial intelligence (AI)-based biomarker study which performed better than existing imaging biomarkers on evaluating the severity of hepatic fibrosis in non-alcoholic steatohepatitis (NASH) patients. If future studies hold true, doctors and medical professionals may one day use a new imaging biomarker extracted from MRI/MRE images to diagnose NASH early and save more lives.

Non-alcoholic fatty liver disease (NAFLD) affects 25 percent of the global population. For 20 percent of these patients, NAFLD leads to a more severe disease called NASH, according to the World Health Organization (WHO). Within the high-risk population of NASH patients, disease evolution can lead to cirrhosis and liver cancer.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.